
































































Some	 allosteric	 inhibitors	 have	 been	 approved	 and	 others	 are	 in	 the	 early	 stages	 of	 clinical	 trials.	 Gleevec®	 was	
approved	in	2002	for	the	treatment	of	chronic	myeloid	leukaemia	and	gastrointestinal	stromal	tumours,	being	the	first	
compound	proven	to	inhibit	a	kinase	by	binding	the	DFG-out	allosteric	site	[8].	Nexavar®	was	approved	in	2005	for	the	
treatment	 of	 renal	 cell	 carcinoma	 and	 hepatocellular	 carcinomas,	 while	 BIRB-796,	 developed	 as	 a	 treatment	 for	
rheumatoid	arthritis	and	Crohn’s	disease,	was	withdrawn	from	phase	III	clinical	trials	[9].	







these	 interactions	will	 lead	 to	 a	 deeper	 knowledge	 of	 the	 structure	 activity	 relationships	 and	 to	 propose	 further	
modifications	to	improve	the	inhibitors.	
The	usual	 approximation	 to	 predict	 the	 interaction	mode	between	 a	 ligand	 and	 a	 receptor	makes	 use	 of	 docking	






the	 ligand-protein	 complexes	obtained	 through	docking,	by	means	of	a	more	accurate	methodology,	 substantially	
improves	 the	 correlation	 between	 experimental	 and	 calculated	 results	 [14,	 15].	 One	 of	 the	 most	 widely	 used	






















between	 a	 number	 of	 options	 in	 this	 protocol	 and	 decide	 the	 most	 appropriate	 methodology	 for	 the	 study	 of	





On	 the	 other	 hand,	 apart	 from	 the	 analysis	 of	 methodologies,	 we	 plan,	 once	 the	 best	 method	 for	 each	 set	 is	


































without	 change	 to	 a	 different	 position.	 Thus,	 the	 substructures	 of	 the	 compounds	 highlighted	 in	 Figure	 2	 were	






















ligand-protein	 set,	 having	 also	 a	 root	 mean	 square	 deviation	 (rmsd)	 between	 them	 higher	 than	 0.05	 Å,	 were	
subsequently	subjected	to	a	minimization	following	the	already	explained	protocol.	
Binding	free	energy	calculation	
Binding	 free	energies	 (ΔGbind)	were	calculated	using	 the	MMPB(GB)SA	algorithms	 implemented	 in	 the	MMPBSA.py	
program	[42].	Thus,	the	binding	free	energy	is	computed	as	the	difference:	∆𝐺#$%& = ∆𝐺()*+,-. − (∆𝐺+1)2-$% + ∆𝐺,$45%&)				(1)	
and	each	term	can	be	estimated	as	follows:	∆𝐺 = 	∆𝐺8 + 	∆𝐺9), = ∆𝐻;;8 − 𝑇∆𝑆8 + ∆𝐺9), 				(2)	
with	 the	 0	 superscript	 referring	 to	 values	 in	 vacuo,	 being	∆𝐻;;8 the	molecular	mechanics	 free	 energy,	∆𝐺9), 	 the	
solvation	free	energy,	and	𝑇∆𝑆8	the	entropic	contribution.	The	molecular	mechanics	energy	is	in	turn	calculated	as	a	
sum	of	the	internal,	electrostatic	and	van	der	Waals	interactions:	∆𝐻;;8 = 	∆𝐻$%28 + 	∆𝐻-,-8 + ∆𝐻>&?8 			(3)	








































	 	 1	snapshot	 MD	
	 Method	 Docking	 PB	 GB	 PB	2	ns	 PB	1	ns	
	 Parameters	 	 εi=0.8	 εi=1	 εi=2	 εi=0.8+S	 εi=1+S	 εi=2+S	 5	 2	 5+S	 2+S	 εi=1	 εi=1	
Protein	 	 	             
B-Raf	 %S	 63.64	 45.45	 81.82	 100.00	 81.82	 81.82	 100.00	 63.64	 81.82	 63.64	 81.82	 81.82	 81.82	
Sp	 0.17	 -0.25	 0.46	 0.54	 0.55	 0.65	 0.67	 -0.12	 0.55	 0.59	 0.65	 0.49	 0.40	
r	 0.05	 -0.36	 0.48	 0.82	 -0.42	 0.65	 0.85	 0.19	 0.52	 0.41	 0.65	 0.62	 0.60	
c-Abl	 %S	 63.64	 63.64	 63.64	 54.55	 63.64	 63.64	 63.64	 63.64	 63.64	 63.64	 63.64	 45.45	 45.45	
Sp	 0.66	 0.57	 0.66	 -0.19	 0.54	 0.46	 -0.15	 0.52	 0.58	 0.38	 0.31	 0.69	 0.69	
r	 0.72	 0.49	 0.57	 -0.08	 0.44	 0.44	 -0.17	 0.43	 0.51	 0.29	 0.38	 0.59	 0.55	
p38⍺	Gleevec®	 %S	 63.64	 100.00	 63.64	 27.27	 100.0	 81.82	 27.27	 45.45	 63.64	 63.64	 81.82	 81.82	 81.82	
Sp	 -0.09	 0.87	 0.47	 -0.63	 0.71	 0.59	 -0.69	 -0.18	 0.21	 0.24	 0.44	 0.68	 0.64	
r	 -0.03	 0.93	 0.60	 -0.78	 0.89	 0.76	 -0.69	 0.03	 0.43	 0.48	 0.65	 0.67	 0.67	
p38⍺	Nexavar®	 %S	 81.82	 81.82	 63.64	 27.27	 81.82	 63.64	 27.27	 63.64	 63.64	 63.64	 63.64	 81.82	 81.82	
Sp	 0.20	 0.63	 0.33	 -0.33	 0.41	 0.16	 -0.45	 0.01	 0.23	 -0.13	 0.05	 0.65	 0.60	
r	 0.39	 0.63	 0.20	 -0.53	 0.49	 0.17	 -0.53	 0.03	 0.28	 0.00	 0.21	 0.57	 0.61	
p38⍺	BIRB-796	 %S	 81.82	 100.00	 63.64	 27.27	 100.0	 81.82	 27.27	 45.45	 63.64	 63.64	 63.64	 100.00	 81.82	
Sp	 0.48	 0.73	 0.52	 -0.51	 0.77	 0.73	 -0.38	 0.23	 0.60	 0.35	 0.60	 0.73	 0.76	
r	 0.64	 0.83	 0.60	 -0.52	 0.90	 0.74	 -0.45	 0.33	 -0.08	 0.45	 0.64	 0.84	 0.85	
		
Some	conclusions	can	be	extracted	from	these	data.	First,	comparison	of	the	scoring	parameters	for	1	ns	and	2	ns	MD	



















Table	1	allows	to	see	that	 the	 influence	of	 the	εi	value	depends	on	the	set	studied.	Thus,	 results	 for	 the	B-Raf	set	
improve	when	εi	increases,	reaching	a	100%	of	success	and	a	Pearson’s	correlation	coefficient	of	0.85	for	εi=2	+	S.	In	
the	case	of	 the	p38α	Gleevec®	set	%S	 improves	 from	27.3%	with	εi=2.0	 to	100%	with	εi=0.8,	all	 remaining	scoring	
























B-Raf	 c-Abl	 p38α	Gleevec®	 p38α	Nexavar®	 p38α	BIRB-796	
Experimental	 εi	 Experimental	 εi	 Experimental	 εi	
Ligand	 0.8	 1.0	 2.0	 Ligand	 0.8	 1.0	 2.0	 Ligand	 0.8	 1.0	 2.0	 0.8	 1.0	 2.0	 0.8	 1.0	 2.0	
7	 1	 8	 8	 6	 8	 8	 1	 7	 3	 3	 10	 9	 9	 10	 3	 3	 10	
2	 8	 3	 3	 8	 3	 3	 4	 9	 9	 9	 1	 3	 3	 9	 8	 8	 3	
3	 3	 9	 9	 1	 6	 6	 5	 3	 6	 8	 4	 7	 10	 8	 7	 7	 5	
11	 10	 7	 6	 9	 9	 9	 10	 6	 7	 6	 5	 8	 8	 5	 9	 9	 1	
6	 9	 6	 7	 2	 7	 1	 8	 2	 8	 10	 3	 10	 7	 3	 6	 6	 4	
9	 4	 2	 2	 11	 2	 7	 3	 11	 2	 1	 9	 6	 5	 4	 11	 10	 8	
8	 7	 1	 11	 10	 11	 2	 6	 8	 11	 7	 8	 2	 2	 1	 2	 5	 9	
1	 6	 10	 10	 7	 1	 11	 9	 1	 1	 2	 6	 5	 6	 7	 10	 11	 7	
4	 2	 4	 4	 3	 10	 10	 7	 4	 10	 11	 7	 11	 1	 2	 5	 1	 6	
5	 5	 11	 1	 4	 4	 4	 2	 5	 5	 4	 2	 4	 11	 6	 1	 2	 2	


























approaches	predict	the	same	ligand	conformations	(poses)	to	be	analysed,	 it	 is	better	to	use	the	MD	run,	as	 it	will	
allow	to	have	information	about	the	strength	of	established	H-bonds.	Thus,	for	this	set	we	will	analyse	the	structures	
from	a	snapshot	extracted	after	1	ns	of	MD.	










	 Experimental	 One	snapshot	 MD	
	 	 	 	 	 	 	
Protein	 Ligand	 IC50	(nM)	 Ligand	 Pose	 ΔGbind	 Ligand	 Pose	 ΔGbind	
B-Raf	 	 	 	 	 PB	εi=2+S	 	 	 PB	εi=1	
	 7	 <1	 8	 5	 -138.5	 8	 2	 -112.5	(0.3)	
	 2	 76.2	 3	 1	 -136.3	 9	 4	 -104.7	(0.4)	
	 3	 83.4	 9	 4	 -133.8	 7	 5	 -100.3	(0.3)	
	 11	 92.3	 6	 5	 -124.0	 6	 5	 -97.7	(0.3)	
	 6	 180.1	 7	 5	 -123.1	 3	 1	 -96.6	(0.4)	
	 9	 236.7	 2	 4	 -122.1	 2	 4	 -94.3	(0.2)	
	 8	 413.9	 11	 5	 -112.8	 10	 4	 -91.7	(0.7)	
c-Abl	 	 	 	 	 PB	εi=1.0	 	 	 	
	 6	 <1	 8	 2	 -113.32	 8	 2	 -114.7	(0.3)	
	 8	 8.6	 3	 1	 -107.12	 6	 2	 -105.0	(0.3)	
	 1	 10.8	 6	 3	 -101.77	 3	 2	 -102.8	(0.4)	
	 9	 62.6	 9	 9	 -99.91	 9	 9	 -100.4	(0.3)	
	 2	 225.9	 1	 7	 -98.45	 7	 2	 -97.7	(0.3)	
	 11	 244	 7	 2	 -92.79	 1	 1	 -95.8	(0.3)	
	 10	 572.4	 2	 2	 -87.05	 2	 2	 -88.1	(0.3)	
p38α	Gleevec®	 	 	 	 	 PB	εi=0.8	 	 	 	
	 7	 <1	 3	 5	 -91.1	 3	 6	 -108.0	(0.4)	
	 9	 <1	 9	 1	 -83.6	 9	 8	 -102.5	(0.3)	
 11 
	 3	 4	 6	 7	 -78.5	 8	 18	 -101.7	(0.3)	
	 6	 18.4	 7	 3	 -77.8	 6	 7	 -99.8	(0.3)	
	 2	 84.8	 8	 18	 -77.0	 1	 11	 -95.0	(0.4)	
	 11	 105.5	 2	 4	 -71.1	 7	 3	 -92.5	(0.2)	
	 8	 189.3	 11	 16	 -68.9	 2	 4	 -84.0	(0.3)	
p38α	Nexavar®	 	 	 	 	 PB	εi=0.8	 	 	 	
	 7	 <1	 9	 9	 -76.6	 3	 5	 -102.7	(0.4)	
	 9	 <1	 3	 5	 -75.7	 8	 2	 -98.6	(0.4)	
	 3	 4	 7	 5	 -69.8	 9	 14	 -95.3	(0.3)	
	 6	 18.4	 8	 16	 -68.9	 7	 5	 -87.2	(0.4)	
	 2	 84.8	 10	 19	 -65.6	 6	 20	 -84.9	(0.3)	
	 11	 105.5	 6	 18	 -65.1	 5	 2	 -84.2	(0.4)	
	 8	 189.3	 2	 15	 -64.3	 2	 15	 -80.0	(0.3)	
p38α	BIRB-796	 	 	 	 	 PB	εi=0.8+S	 	 	 	
	 7	 <1	 3	 8	 -90.2	 8	 6	 -106.1	(0.6)	
	 9	 <1	 7	 3	 -82.5	 3	 8	 -104.8	(0.3)	
	 3	 4	 8	 20	 -75.1	 7	 3	 -93.9	(0.2)	
	 6	 18.4	 6	 13	 -70.6	 6	 4	 -93.4	(0.3)	
	 2	 84.8	 11	 10	 -69.1	 9	 9	 -91.6	(0.3)	
	 11	 105.5	 9	 18	 -66.5	 2	 8	 -86.4	(0.3)	










of	MD	are	almost	 identical.	We	decided	 to	analyse	 the	one-snapshot	poses	as	 the	 relative	 ranking	 for	 the	 ligands	



















































Figure	4:	Non-polar	and	polar	 contributions	 to	 free	binding	energy	 for	 selected	 residues	of	B-Raf,	 c-Abl	 and	p38α	
interacting	with	different	 ligands.	(a)	and	(b)	correspond	to	non-polar	and	polar	contributions	for	B-Raf	 interacting	




Focussing	 on	 the	 comparison	 between	 ligands	 2	 (IC50	 =	 76.2	 nM)	 and	 7	 (IC50	 <	 1	 nM),	 Figure	 5	 compares	 both	
predicted	structures.	As	seen	in	Table	4S,	B-Raf	establishes	similar	H-bonds	with	both	ligands	(through	GLU501,	CYS532	



















stronger	 interactions	 for	 residues	 VAL471,	 VAL482	 and	 VAL528	 are	 caused	 by	 the	 change	 from	 benzene	 to	
naphthalene.	From	this	data,	we	suggest	that	a	 ligand	with	naphthalene	in	the	central	core	as	 ligand	7,	but	with	a	
heteroaromatic	moiety	instead	of	the	morpholine	ring	(so	that	it	can	establish	π-π	interactions	with	TRP531),	would	





the	 common	 substructures	 to	 overlap	 (Figure	 4S),	 while	 the	 1-chloro-2-(trifluoromethyl)benzene	 ring	 of	 ligand	 6	
occupies	a	zone	different	than	that	occupied	by	the	1-methyl-piperazine	ring	of	Gleevec®.Figure	6	allows	to	realise	
that	the	relative	conformation	adopted	by	the	1-chloro-2-(trifluoromethyl)benzene	ring	in	ligand	6	is	precisely	that	




displays	 the	extended	H-bond	 interaction,	even	 improved	with	an	additional	H-bond	 from	LYS271	 to	GLY383.	The	
superposition	of	the	conformations	adopted	by	the	ligands	docked	into	c-Abl	studied	in	the	present	work	with	that	of	
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influence	 of	 protein	 structure	 on	 those	 conformations.	 The	 analysis	 of	 the	 superimposed	 ligand	 structures	when	
complexed	with	p38α	(Figure	5S)	confirms	that	the	common	substructure	has	maintained	its	position,	and	shows	the	
conformations	adopted	by	Gleevec®	and	Nexavar®	 in	 the	experimental	structures	 to	be	slightly	different	 from	the	
theoretical	ones.	These	differences	are	higher	for	Nexavar®,	with	the	N-methylformamide	rotated	180°.	Nevertheless,	
the	H-bond	established	between	the	nitrogen	atom	of	the	pyridine	ring	bound	to	N-methylformamide	and	MET109	in	































































































• Re-scoring	 after	 a	 docking	 procedure	 is	 a	 computationally	 cheap	 and	 useful	methodology	 to	 improve	 the	
quality	of	results	
• Using	 just	 one	 snapshot	 within	 the	 MMPB(GB)SA	 methodology,	 together	 with	 a	 rational	 comparison	 of	
different	parameters,	could	be	as	useful	as	a	long	MD	run	
• When	the	set	to	be	studied	is	big	an	a	priori	protocol	would	be	to	use	one	snapshot	MMPBSA	with	no	entropic	
term	and	choose	εi	according	to	the	charge	of	protein	and	ligands	
• B-Raf	could	be	increased	modifying	ligand	7	with	an	heteroaromatic	moiety	instead	of	the	morpholine	ring	
• c-Abl	inhibition	could	be	increased	modifying	Gleevec®	by	changing	the	acetamide	linker	with	a	urea	type	one	
• p38α	inhibition	could	be	increased	by	changing	the	1-methyl-piperazine	ring	with	a	non-charged	heterocycle	
being	able	to	establish	an	H-bond	with	HIS148	
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